Jeffrey Stein compensation by year
Cidara Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2023 | FY2024 |
|---|---|---|
| Salary | $593,800 | $617,600 |
| Bonus | $0 | $0 |
| Stock awards | $274,468 | $0 |
| Option awards | $388,276 | $4,867,353 |
| Non-equity incentive | $292,100 | $470,600 |
| Pension and deferred compensation | $0 | $0 |
| All other | $9,900 | $10,350 |
| Total | $1,558,544 | $5,965,903 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cidara Therapeutics, Inc. DEF 14A filed April 25, 2025, accession 0001610618-25-000040, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Cidara Therapeutics, Inc. filed document, accession 0001610618-25-000040. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 9,058 | $243,479 | — |
| RSU | 2,723 | $73,194 | — |
| Option | 1,375 | — | $16.65 |
| Option | 514,147 | — | $10.75 |
| Option | 11,319 | — | $20.20 |
| Option | 38,994 | — | $13.70 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Cidara Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
34 Form 4 lines since the FY2024 proxy (filed April 25, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-01-07 | Disposition to the issuer | — | 2,379 | $221.50 | 0 |
| 2026-01-07 | Disposition to the issuer | — | 67,498 | $221.50 | 0 |
| 2026-01-07 | Disposition to the issuer derivative | — | 7,949 | — | 0 |
| 2026-01-07 | Disposition to the issuer derivative | — | 11,000 | — | 0 |
| 2026-01-07 | Disposition to the issuer derivative | — | 11,749 | — | 0 |
| 2026-01-07 | Disposition to the issuer derivative | — | 13,249 | — | 0 |
| 2026-01-07 | Disposition to the issuer derivative | — | 16,499 | — | 0 |
| 2026-01-07 | Disposition to the issuer | — | 5,763 | $221.50 | 0 |
The 8 most recent of 34 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Cidara Therapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Jeffrey Stein · this page | President and Chief Executive Officer | $5,965,903 |
| Leslie Tari | Chief Scientific Officer | $2,040,404 |
| Taylor Sandison | Former Chief Medical Officer | $2,015,225 |
The full Cidara Therapeutics compensation record
free company briefThis page is one person within Cidara Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cidara Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.